Clinical TrialRx — Clinical Trial & RWE Rescue · When trials go off-course, we put them back on target

Our Track Record · Delivery Proof

What rescue looks like when frameworks meet operators.

Outcomes measured across 300+ protocols and 900+ projects — the portfolio behind every engagement we deliver.

$302M

Revenue Growth · 19 Months

Record growth driving operations and commercialization alignment under First Choice global sales strategy.

$107M

Actual-vs-Plan Revenue Lift

New revenue through three CRO and technology partnerships; expanded RWE/RWD pipeline.

38 days

Data-Lock Acceleration

Average interim and final data locks ahead of schedule across managed programs.

98%

SOW / UAT Error Reduction

Set-up errors per protocol reduced through the 5-Gate Stage-Gate review system.

97%

Studies On-Budget

Studies delivered within sponsor-approved budget across 300+ protocols managed.

94%

Sponsor Complaints Reduced

Client issues reduced through Client Delight COE deployment and VOC governance.

45%

Amendment Cycles Cut

Rescue-trial amendment cycles reduced through submissible RWE packs for FDA, EMA, PMDA, TGA, HSA.

30%

Operational Efficiency Lift

Improvement in underperforming clinical operations divisions — 15 high-priority trials in 18 months.

Proven across 300+ Protocols · 900+ Projects · 22 Therapeutic Areas · Concept → Post-Market RWE

The Problem · 2025 Industry Data

Why 80% of clinical trials miss their timelines — and what it actually costs sponsors.

Trial delays don't come from one failure. They compound across start-up, site activation, recruitment, and contracting — each adding months, amendment cycles, and burn. The data below maps where pharma, biotech, and device programs are losing the race.

Industry Signal · Flagged for Rescue

If your trial is showing any two of the signals below, it's statistically already off-course — and the longer it waits, the more expensive the rescue.

Signal 01 · Timeline

80^%

Miss original timelines

Of industry clinical trials fail to meet initial enrollment dates and delivery milestones — caused by underperforming sites, missed recruitment, and inefficient study review.

Source: WCG / Fierce Biotech · 2025

Signal 02 · Contracts

92^%

Contract & budget cited as #1 fix

Of clinical sites identify contract and budget support as the top area where both sponsors and CROs can improve, a near-unanimous diagnosis of the most fixable bottleneck in trial start-up.

Source: ICON Site Survey · 2025

Signal 03 · Governance

66^%

Contract delays "often or always"

Of sites experience contract and budget delays repeatedly across studies — a systemic governance failure, not a one-off negotiation issue.

Source: ICON Site Survey · 2025

Signal 04 · Retention

23^%

Participant dropout

Of participants who enroll in a trial fail to complete it — compounding sample-size risk, power loss, and the need for protocol amendments mid-study.

Source: WCG · 2025

Signal 05 · Cadence

17^mo

Avg. inter-trial interval

Gap between trial phases across global sponsors — timeline-widening lag attributed to siloed data systems, manual workflows, and regulatory heterogeneity across regions.

Source: IQVIA Global Trends R&D · 2025

Signal 06 · Operations

60^%

Operational inefficiency cited

Of surveyed R&D executives identify lab workflow inefficiencies, outdated systems, and siloed data as the top barriers to innovation and timeline adherence.

Source: Deloitte Center for Health Solutions

Voice-of-Client Advocacy

The 7 reasons sponsors say NO to CROs — and the levers that turn each into YES.

Our Client Delight Center of Excellence is built on a seven-part diagnostic of sponsor dissatisfaction. Every engagement begins with a VOC audit — because a rescue that doesn't address why the trust broke will break again.

Framework developed across
25+ international Phase I–IV rescues
and a $1B / 5-year BD initiative at a Tier-1 global central laboratory firm

Price

Bid misaligned to delivered value; change-order surprises; TCO never surfaced.

Strategy

Operational plan disconnected from sponsor's portfolio goals and regulatory strategy.

Relationships

No C-suite advocate; steering committee disengaged; PM turnover destroys continuity.

Retention

Key study staff churn mid-program; institutional knowledge walks out the door.

Communication

Late, filtered, or sanitized escalation; sponsor learns of risk at data lock, not at gate review.

Accountability

Action items with no owner; metrics reported but not governed; issues recur across studies.

Executive Knowledge

CRO senior leadership absent from critical milestones; no strategic depth on escalation.

→

YES Lever Activation

Each NO is re-engineered as a YES lever through our Client Delight COE — governed, measured, owned.

Service Lines · What We Deliver

Every capability a sponsor needs — under one delivery architecture.

Most consultancies offer slices: monitoring only, RWE only, commercial only. We deliver the full clinical operations stack — concept through post-market — so handoffs don't fail and accountability never disperses. Twelve service lines, four categories, one operator.

Category I · Trial Execution

End-to-end study delivery across every phase and design — interventional, observational, hybrid.

01 · Phase I → IV + RWE / RWD

Service 01

Phase I First-in-Human

FIH, dose escalation, MAD/SAD, PK/PD studies. Site selection, IRB submission, safety review board orchestration, real-time AE adjudication.

Lifecycle CoverageFIH → DSMB

Service 02

Phase II Proof of Concept

Dose-finding, signal detection, adaptive POC designs. Bayesian and frequentist endpoints, biomarker integration, futility analysis.

Design RangeAdaptive · Basket · Umbrella

Service 03

Phase III Pivotal & Registrational

Multi-country pivotal trials at scale. $875M Phase III directed end-to-end across 175+ sites in 25+ countries; 50,000+ screened, 10,000+ randomized.

Peak Scale Directed$875M · 25+ Countries

Service 04

Phase IV Post-Market

Label expansion, safety surveillance, observational Phase IV programs. Long-term follow-up, RMP/REMS execution, signal-detection programs across multi-indication post-market portfolios.

Reference ScopePhase IV Observational · Multi-Site Global

Service 05

RWE Observational & Registries

NIS, PASS, pragmatic Phase IV, PRO, disease and product registries. Methodologically rigorous designs aligned to FDA, EMA, PMDA reliance pathways.

Submission ReadyFDA · EMA · PMDA · TGA · HSA

Service 06

RWD Strategy & Data Lakes

Real-world data-lake architecture, claims and EHR integration, systematic literature review, submissible evidence packs for orphan and rare-disease assets.

Amendment Reduction45% Cut

Category II · Quality, Oversight & Rescue

The governance layer — risk-based monitoring, auditing, and trial rescue across every phase, every design. Phase I through Phase IV, plus RWE/RWD registries. No phase is too late, no design too complex.

02 · Monitor · Audit · Rescue All Phases

Service 07

Risk-Based Monitoring

Centralized and on-site RBM teams via FSP governance, resource allocation by site risk profile, AI/ML-driven anomaly detection, source data verification optimization.

SDV Workload CutUp To 60%

Service 08

Quality & Auditing

GCP audits, vendor and CRO audits, regulatory inspection readiness, mock FDA/EMA inspections, CAPA management, deviation root-cause analysis.

Authorities EngagedFDA · EMA · PMDA · TGA · HSA

Service 09 · Signature

Clinical Trial Rescue — Every Phase

The headline offering. We rescue at every phase, every design, every geography. Phase I FIH safety studies that lost their PI. Phase II POCs missing enrollment by 80%. Phase III pivotals with data integrity questions. Phase IV post-marketing studies on regulatory hold. RWE/RWD registries with submissible-evidence gaps. All of it.

Rescued Across PhasesI · II · III · IV · RWE

Category III · Commercial & Win Solutions

Win more bids. Close bigger deals. Convert sponsor NOs into YES — using the same frameworks that drove a $1B / 5-year BD initiative.

03 · Bid Defense · Sales · BD

Service 10

Bid Defense Solutions

Cross-functional bid defense methodology developed and chaired at a Tier-1 global central laboratory firm. Win-strategy playbook per account, C-suite advocacy, competitive positioning.

BD Portfolio Chaired$1B / 5-Year Initiative

Service 11

Sales & BD Strategy

First Choice global sales strategy bridging BD, Operations, PM, and Commercialization. AOP alignment, pipeline architecture, Fortune 100 sponsor engagement.

Record Growth Delivered$302M in 19 Months

Service 12

Client Delight Activation

VOC-7 diagnostic deployment — turn the seven reasons sponsors say NO into governed YES levers. Lift retention, expand wallet share, restore C-suite trust.

Sponsor Complaints Reduced94% · VoC Lift 78%

Engagement Architecture · SVAM Model · Origin Story

Five engagement tiers. Scale as far as your program needs.

The twelve service lines above? They can be deployed at any tier of engagement. The Service Value Added Model (SVAM) lets sponsors scale from targeted staffing augmentation through full strategic partnership — transparent upgrade paths, outcome-aligned pricing, zero bid-defense translation loss between what we promise and what we deliver.

Why SVAM exists: the framework was born when we architected the first FSP transition for the world's #1 staffing company — an engagement to evolve their delivery from pure staff augmentation to a true service-line model. The five tiers below are the path we mapped them through, and the path every sponsor can now traverse with us.

Tier L1

Staffing

Targeted resource augmentation — senior operators embedded into your existing clinical team to unblock capacity constraints.

Interim CPM / TPM / Ops leads
CRA / monitoring surge
Regulatory & submission specialists
Rapid deploy · 2–4 wk

Tier L2

Limited Service

Scoped functional deliverables — discrete work packages with defined SOW, timeline, and acceptance criteria.

Start-up & site activation rescue
Data-lock acceleration sprints
Protocol amendment authoring
Risk-based monitoring deploy

Tier L3 · Signature

Personnel
& Governance

Managed teams with embedded governance — the most common rescue entry point. Full-functional or cross-functional team under our delivery oversight.

FSP team deployment
Full CRO oversight & metrics
Client Delight COE active
Stage-Gate G1–G5 governance

Tier L4

Operational Partnership

End-to-end study or program delivery — trial rescue from diagnosis through data-lock, submission-ready evidence, and close-out.

Full trial turnaround ownership
Portfolio-level PM-COE
RWE/RWD COE standards
Regulatory submission support

Tier L5

Strategic Partnership

Multi-program, multi-year — operating as the sponsor's extended clinical operations leadership with shared outcome accountability.

Fractional CCO / Head of Ops
Annual Operating Plan alignment
Portfolio-wide delivery metrics
Advisory & board-level support

Delivery Methodology

Two processes. Five gates. Zero translation loss.

Our Business Acquisition Process (BAP) and Business Execution Process (BEP) run as paired systems — every commitment made in the bid phase is operationalized into execution without the handoff failure that kills most sponsor engagements.

BAP — Business Acquisition Process

Stage-gated commercial pipeline from first interest through contract. Turns sales from art into a repeatable system.

01 · Commercial

Interest

Inbound signal or outbound target

Qualify

Fit, budget, decision authority

Pursue

Stakeholder mapping, strategy

Bid

Proposal & bid defense

Negotiate

Terms, indemnity, SOW

Win

Contract → handoff to BEP

BEP — Business Execution Process

Execution counterpart to BAP. Every sales commitment operationalized — seamless handoff from won to delivered.

02 · Execution

Define

Scope, charter, success metrics

Initiate

Team stand-up, KOM, governance

Plan

Risk register, critical path, SOP

Execute

Site activation, enrollment, monitoring

Monitor

Metrics, gate reviews, amendments

Data lock, CSR, submission-ready

5-Gate Stage-Gate Review System

Formal evaluation at every phase — risk surfaced early rather than at data lock. Matches management intensity to project complexity.

03 · Governance

Strategy

Scope, fit, go/no-go

Planning

Protocol, budget, risk

Readiness

Sites, systems deployable

Excellence

Mid-study delivery

Close-Out

Data lock, CSR, sub

Capability Pillars · Centers of Excellence

Four proprietary COEs. Deployable into any sponsor environment.

Every rescue draws on four permanent Centers of Excellence — built across 30+ years of global operations and adopted across pharma, biotech, device, and academic sponsors.

FSP · Functional Service Provider

Outsourced delivery,
sponsor-retained control.

Governance architecture used for 25+ international Phase I–IV trial rescues. Sponsor retains visibility, communication, and quality authority while we carry execution load — the architecture competitors cite but rarely deliver.

25+ Rescues Global Deploy Pharma · Biotech · Device · Academia

Client Delight COE

The "YES" system
— engineered, not aspirational.

Systematic approach combining Clinical-RWE Operations and Project Management across Phase I–IV, Late Phase, RWE, and Central Lab studies. Each of the 7 NOs in the VOC framework becomes a YES lever — governed, measured, owned.

VOC Diagnostic 7-Lever Activation Customizable

RWE / RWD COE

Submission-grade real-world evidence, not post-hoc.

Standards, training, and delivery across 20 countries. Systematic literature review and real-world data-lake strategies producing FDA, EMA, PMDA, TGA, and HSA-submissible evidence packs. Observational, registry, PASS, PRO, HEOR, and pragmatic Phase IV designs.

FDA · EMA · PMDA TGA · HSA 45% Amendment Cut

PM-COE · Four Established

Project management, operationalized for clinical.

Four PM Centers of Excellence built across the Americas, EU, and APAC. Standardized processes, training, and earned-value metrics lift delivery efficiency and client satisfaction across 20+ countries. Integrates with AI/ML-driven trial analytics.

4 COEs Built AI/ML Analytics Adaptive Designs

AI/ML · Industry-First Offering

Clinical trial operations, augmented by AI/ML — not retrofitted with it.

Most consultancies are bolting AI/ML buzzwords onto traditional services. We're operating from the other end: our leadership pioneered AI/ML in clinical trial operations, serving as lead advisor on a first-mover voice-activated AI/ML predictability platform that secured global IP, Series funding, and Fortune 100 acquisition partners.

That depth means our AI/ML isn't theater. It's threaded through the four pillars of how we deliver — predictive enrollment, site risk scoring, monitoring triage, signal detection, and submissible evidence generation. The result: faster timelines, lower amendment cycles, and rescue programs that recover in months, not years.

Authored: AI/ML-Driven Trial Analytics · Risk-Based Monitoring Platforms
Deployed: Across 30 Countries · 300+ Protocols · 900+ Projects
Founder Track Record: 4-Time Start-Up Operator · Exits to Salesforce & Oracle

AI Module 01

Predictive Enrollment

ML models forecast site-level enrollment trajectories from screening, recruitment, and historical performance — flagging shortfalls 60+ days ahead of timeline impact.

AI Module 02

Site Risk Scoring

Dynamic risk profiling across data quality, deviation rate, query velocity, and PI engagement — feeds the Risk-Based Monitoring queue automatically.

AI Module 03

Monitoring Triage

Centralized monitoring algorithms surface anomalies in SDV, AE reporting, and protocol deviations — directing CRA effort to the 20% of sites driving 80% of risk.

AI Module 04

Signal Detection (PV)

Pharmacovigilance signal-detection models for safety and efficacy in post-market and RWE programs — surface trends ahead of mandatory reporting windows.

AI Module 05

Data-Lake Generation

Real-world data-lake architecture ingesting claims, EHR, registry, and PRO data. Producing FDA/EMA/PMDA-submissible evidence packs at 45% fewer amendment cycles.

AI Module 06

Bid Scoring & VOC

ML-driven bid-defense win-rate modeling and Voice-of-Client diagnostic — predicting where sponsor relationships will fracture before they do, with intervention pathways.

F500 Sponsor Engagement · The $10M+ Build-Transfer-Exit Tier

Build. Transfer. Exit.
You own the system in 18 months.

Most consultancies sell perpetual engagement — they build, then they stay. We don't. The Build-Transfer-Exit (BTE) Model architects an internal AI/ML clinical operations capability that your team owns and runs, with us out of the building by month 18. Built specifically for F500 pharma sponsors targeting 30%+ headcount efficiency without sacrificing pipeline velocity.

$10M

Engagement Investment
18-Month Pilot Build

→

35%

Clinical Ops
Headcount Reduction

$42M⁺

Annual Run-Rate Savings
Year 2 Forward

18-month payback · 4.2× return year 1 · Pure margin year 2 onward

Phase 01 · Build

Months 1 → 6

Build

Embedded senior operator plus AI/ML engineering team architect the data-lock orchestration platform. Integrate with sponsor's EDC, CTMS, Veeva Vault, and PV systems. Deploy live in pilot therapeutic area. Co-author governance with sponsor's Head of Clinical Operations.

AI/ML model architecture + training
System integration & pilot TA live
Governance framework co-authored
Quarterly board reviews initiated

Phase 02 · Transfer · Signature

Months 6 → 12

Transfer

Sponsor team trained, certified, and progressively assumes operations. Side-by-side delivery becomes shadow delivery becomes hands-off. IP transferred under sponsor ownership. Internal champions identified and elevated to platform leadership.

Sponsor team trained & certified
Operations handed off by TA
Full IP transferred to sponsor
Internal champions in platform lead roles

Phase 03 · Exit

Months 12 → 18

Exit

Sponsor owns and runs the system end-to-end. We provide quarterly advisory only. Headcount efficiency targets validated to the board, ROI booked, internal team fully autonomous. Clean exit with optional ongoing advisor retainer.

Sponsor fully autonomous
ROI validated to board
Headcount targets met or exceeded
Optional advisor retainer only

Embedded Operator

Donald Ray Cook, M.S.ML

Ed.D. (Expected 2026). 30+ years global clinical operations. Four-time start-up operator. Architect of the first FSP transition for the world's #1 staffing company — the engagement that gave birth to the SVAM framework. Direct day-one engagement, no junior handoff.

Engagement Scale

$5M – $50M+

Right-sized to therapeutic area complexity and sponsor portfolio breadth. Single-TA pilots start at $5M; full portfolio transformations scale to $50M+ across 24–36 months.

Target Sponsor

F500 Pharma · Biotech · Device

Built specifically for sponsors with 500+ clinical operations FTEs pursuing AI/ML transformation, headcount efficiency, and accelerated submission timelines simultaneously.

Startup Biotech · Emerging Life Sciences

Molecule to approval.For founders who cannot afford to get the first trial wrong.

For startup biotechs and emerging life science companies, we structure smaller, sharper engagements. Fractional CDO/CMO, pre-IND audits, project sprints, and board advisory. The same operator who has architected $875M Phase III programs across 25+ countries, scaled to where you are.

STAGE 01

Discovery & Preclinical

Translational and IND-enabling strategy before you spend a dollar on tox.

Target validation review
IND-enabling roadmap
CMC strategy
Preclinical CRO selection

STAGE 02

IND / CTA Submission

The first regulatory file is also your first credibility statement to acquirers.

Pre-IND meeting prep
Module 2 narrative architecture
Regulatory pathway analysis
Multi-agency strategy

STAGE 03

Phase I FIH

First-in-human is where startup discipline either compounds or unravels.

Protocol & endpoint design
Site & CRO selection
Dose-escalation governance
Safety review setup

STAGE 04

Phase II POC

The proof-of-concept that triggers the next financing round or partnership.

Adaptive trial design
Biomarker strategy
Interim analysis framework
Investor & partner readouts

STAGE 05

Phase III Pivotal

This trial is your company's valuation. We have led $875M Phase III programs.

Pivotal protocol architecture
FSP / CRO governance
Risk-based monitoring
End-of-Phase II / SPA

STAGE 06

BLA / NDA Submission

The submission is a 12-month sprint. Preparation is a 24-month design choice.

CTD module strategy
Pre-NDA meeting prep
Advisory committee readiness
FDA, EMA, PMDA coordination

STAGE 07

Phase IV / Post-Market

Approval is the start, not the finish. RWE shapes label expansion and payer access.

Post-marketing commitments
REMS architecture
Phase IIIb / IV design
Pharmacovigilance setup

STAGE 08

RWE / RWD Programs

Beyond the label: market access, payer dossiers, and the data engine behind them.

RWE study design
Data-lake architecture
HEOR & payer evidence
Registry & observational

Startup Engagement Models

Pick the shape that fits your stage and runway.

Tier S1 · Pre-IND Diagnostic

Pre-IND Strategic Audit

Fixed-scope · 4 to 6 weeks

Independent assessment of your translational data, IND-enabling roadmap, CMC posture, and regulatory pathway choice before you commit to a tox program or a sponsor meeting.

IND-readiness scoring
Regulatory pathway recommendation
CRO / partner shortlist
12-month operational roadmap

Tier S2 · Fractional Operator

Fractional CDO / CMO

Retainer · Monthly · Equity considered

The most common startup engagement. We embed as your fractional Chief Development Officer or Chief Medical Officer, sitting in your weekly clinical operations meetings, your partner conversations, and your board updates.

Clinical operations leadership
Regulatory strategy oversight
Vendor & CRO governance
Board & investor reporting

Tier S3 · Project Sprint

Targeted Project Delivery

Fixed-scope · Defined deliverables

Single-deliverable engagements for specific milestones. IND filing, pre-NDA prep, FSP architecture, Phase III protocol design, or an acquirer-readiness diligence audit.

IND / CTA submission lead
Pivotal trial design
FSP / CRO RFP & selection
Acquirer diligence prep

Tier S4 · Board Advisor

Scientific & Clinical Advisory Board

Equity · Quarterly · As-needed

Lighter-touch role for early-stage companies where the board needs a senior clinical operations voice but the trial work has not started. Often the first step before a fractional engagement.

Board-level clinical advisor
Quarterly strategic reviews
Diligence call support
Partner / investor warmup

Founder Call

Tell us where you are.We'll tell you what we'd do next.

Every founder call begins with a 30-minute conversation: where you are, what's coming, and the two or three operational decisions that will most shape the next 12 months. No deck. No pitch. Just an operator listening.

If we're a fit, we'll propose a path. If we're not, we'll tell you who is.

Email drc@clinicaltrialrx.com

Direct +1 (317) 491-2150

Calendar calendly.com/clinicaltrialrx

Don't fill this out if you're human:

Your Name *

Email *

Company *

Current Stage *

Therapeutic Area

What's on your mind? *

We reply within 24 hours, US business days.
All inquiries treated as confidential.

Why Clinical TrialRx · The Unfair Advantage

No other consultancy combines all seven of these in one operator.

The industry sells you slices — a monitoring firm, an RWE shop, a bid-defense consultant, an AI/ML vendor. We deliver them as one unified architecture, under one operator with delivery proof at every level.

Lever

What Sponsors Need

Industry Standard

Clinical TrialRx

Scale VeteranHas actually run the size of trial you're attempting

Mid-size studies; "team has experience" claims; no first-person scale references.

Directed $875M Phase III end-to-end. 10,000+ patients. 175+ sites. 25+ countries.

Start-Up Operator DNABrings entrepreneurial speed without losing rigor

Career consultants. Process-heavy. Speed sacrificed to method.

Four-time start-up operator. Two exits: Salesforce & Oracle. Plus enterprise rigor.

AI/ML NativePioneered AI/ML in life sciences, not bolting it on

AI buzzwords. White-label vendor wrappers. No proprietary IP.

Lead advisor on first-mover voice-activated AI/ML platform. Global IP secured.

End-to-End LifecycleOne operator from molecule to post-market RWE

Phase-specific specialists. Handoffs to other vendors. Information loss.

Concept → Submission → Post-Market RWE. One operator. Zero handoffs.

Proprietary FrameworksPortable IP that scales — not generic decks

PowerPoint methodology. Recycled industry frameworks. No authoring credit.

Authored: SVAM · BAP · BEP · 5-Gate · Client Delight COE · RWE COE.

Regulatory BreadthDemonstrated submissions across major authorities

FDA-focused. Limited EMA exposure. PMDA/TGA/HSA outsourced.

All five in one operator: FDA · EMA · PMDA · TGA · HSA.

Site · Sponsor · CRO TriadHas operated from all three sides of the table

One vantage point. CRO-only or sponsor-only. Blind spots.

Built 4 CTPs at Indiana sites. Architected the first FSP transition for the world's #1 staffing company — birthplace of SVAM. Led senior roles across Tier-1 global CROs.

Portfolio by Phase · Aggregate Totals

Five phases. 300+ protocols. 22 therapeutic areas.

Three decades of clinical operations directed across every phase of the drug development lifecycle. The portfolio below reports aggregate totals by phase — the scale of trials we've been responsible for, not individual sponsor engagements.

Phase I — First-in-HumanFIH · Dose Escalation · PK/PD · Safety Cohort

Early Phase
Safety + PK/PD

Multi-Site First-in-Human Programs

Dose Escalation · MAD/SAD · Biomarker

Phase II — Proof of ConceptPOC · Dose Finding · Signal Detection

Mid Phase
Efficacy Signal

Adaptive · Basket · Umbrella Designs

Biomarker Integration · Bayesian Endpoints

Phase III — Pivotal & RegistrationalMulti-Therapeutic · Multi-Country · Submission-Bound

$875M+ Peak Budget
Directed End-to-End

10,000+ pts · 175+ sites

25+ Countries · 6 Continents

Phase IV — Post-Market & ObservationalLabel Expansion · Safety Surveillance · RMP/REMS

Post-Market
Long-Term Follow-Up

Observational · Pragmatic Phase IV

Multi-Indication · Signal Detection

RWE / RWD Programs + Trial RescueRegistries · NIS · PASS · PRO · International Rescues

25+ Rescues
Every Phase

Disease & Product Registries

FDA · EMA · PMDA · TGA · HSA Submissions

Operator Portfolio · Three Decades, Documented

The metrics behind the methodology.

Every framework on this site was forged in delivery — global trials, F500 commercial mandates, two start-up exits, and 25+ international rescues. The portfolio below documents the embedded operator's career at a glance.

$875M

Phase III Budget

10,000+ pts · 175+ sites · 25+ countries

$302M

Revenue Growth

19 months · company record

25⁺

Rescues

International Phase I-IV

54/157

Reports Led

Direct / Dotted-Line · 27 PIP Turnarounds

Therapeutic Areas

Oncology · CV · CNS · Rare Disease + more

Countries

Six continents · 1,112+ sites

I-IV+RWE

Full Lifecycle

Concept → submission → post-market

Portfolio Totals

Across All Engagements · Aggregate

Total Studies Directed

The Trial Portfolio

Three decades of clinical trial accountability across every phase, every geography, and every regulatory pathway — from concept through submission through post-market surveillance.

300⁺Protocols Managed

900⁺Projects Delivered

25⁺Int'l Trials Rescued

24,700⁺Patients Enrolled

1,112⁺Clinical Sites

I-IV⁺RWEEvery Phase

Therapeutic Footprint

22 Therapeutic Areas

Multi-indication depth spanning oncology, cardiovascular, CNS / neurology, rare disease, endocrine, immunology, infectious disease, hematology, ophthalmology, and 13 more therapeutic areas across the drug development lifecycle.

22Therapeutic Areas

30Countries

6Continents

FDA · EMAPlus PMDA · TGA · HSA

I → IVFull Lifecycle

RWE · NIS · PASSPlus PRO · Registries

Senior Director · 19 Months · Company Record

Revenue Growth · Commercial Leadership

Company-record commercial mandate spanning global sales strategy, FSP architecture, and PM-COE buildout across three continents.

$302MRevenue Growth

$107MNew Revenue

4PM-COEs Built

78%VoC Lift

$1BBD Initiative Chaired

3Continents

Delivery Excellence Proof · 300+ Protocols · 900+ Projects

38 days

Ahead of Schedule

Average interim & final data-lock acceleration across managed programs

98%

SOW / UAT Error Reduction

Per protocol via 5-Gate Stage-Gate review

97%

Studies On-Budget

Delivered within sponsor-approved budget across 300+ protocols

94%

Sponsor Complaints Reduced

Via Client Delight COE + VOC governance

Donald Ray Cook, M.S.ML

Ed.D. (Expected 2026)

Founder & Embedded Operator. Direct day-one engagement on every F500 sponsor partnership.

Embedded Operator · Founder & Lead Engagement Partner

The operator who will sit at your table. Founder of Clinical TrialRx and lead embedded partner on every F500 sponsor engagement. Four-time start-up operator with exits to Salesforce and Oracle, plus lead-advisor work on a first-mover voice-activated AI/ML predictability platform (global IP, FCC-approved, Series-funded). Three decades operating across the full drug-development lifecycle — molecule discovery, Phase I-IV clinical operations, global regulatory submissions, and post-market RWE/RWD.

Directed an $875M Phase III across 10,000+ patients, 175+ sites, and 25+ countries. Drove $302M in revenue growth in 19 months (company record). Architected the Service Management Framework — SVAM · BAP · BEP · 5-Gate Stage-Gate — adopted across pharma, biotech, medical device, and academic sponsors. SVAM itself was born when we architected the first FSP transition for the world's #1 staffing company moving from staff augmentation to full-service delivery — the five-tier model now maps directly to that lived experience.

Dual perspective across site · sponsor · CRO. Leadership track spans senior operating roles across the world's largest CROs, top-tier global pharma sponsors, biotech innovators, and academic medical centers. Ed.D. candidacy in Leadership and Innovation at Purdue University (expected 2026). M.S. Management & Leadership, Purdue University.

Connect on LinkedIn Schedule Direct

54 / 157Direct / Dotted-Line Reports
Managed Globally Across FSP

27PIP-Graduates Mentored
to Full Performance · 100% Retention

4 + 4PM-COEs Established + CTPs Built
All became global top-enrolling sites

FDA · EMA · PMDA · TGA · HSAAll Major Authorities Engaged
Across Global Submissions

4 Ventures · 2 ExitsStart-Up Operator Track Record
Salesforce · Oracle · Series Funded

AI/ML PioneerLead Advisor · Global IP
FCC-Approved Voice AI Platform

When a trial isoff-course,we put it backon target.

What rescue looks like when frameworks meet operators.

Why 80% of clinical trials miss their timelines — and what it actually costs sponsors.

Miss original timelines

Contract & budget cited as #1 fix

Contract delays "often or always"

Participant dropout

Avg. inter-trial interval

Operational inefficiency cited

The 7 reasons sponsors say NO to CROs — and the levers that turn each into YES.

Price

Strategy

Relationships

Retention

Communication

Accountability

Executive Knowledge

YES Lever Activation

Every capability a sponsor needs — under one delivery architecture.

Category I · Trial Execution

Phase I First-in-Human

Phase II Proof of Concept

Phase III Pivotal & Registrational

Phase IV Post-Market

RWE Observational & Registries

RWD Strategy & Data Lakes

Category II · Quality, Oversight & Rescue

Risk-Based Monitoring

Quality & Auditing

Clinical Trial Rescue — Every Phase

Category III · Commercial & Win Solutions

Bid Defense Solutions

Sales & BD Strategy

Client Delight Activation

Five engagement tiers. Scale as far as your program needs.

Staffing

Limited Service

Personnel& Governance

Operational Partnership

Strategic Partnership

Two processes. Five gates. Zero translation loss.

BAP — Business Acquisition Process

BEP — Business Execution Process

5-Gate Stage-Gate Review System

Strategy

Planning

Readiness

Excellence

Close-Out

Four proprietary COEs. Deployable into any sponsor environment.

Outsourced delivery,sponsor-retained control.

The "YES" system— engineered, not aspirational.

Submission-grade real-world evidence, not post-hoc.

Project management, operationalized for clinical.

Clinical trial operations, augmented by AI/ML — not retrofitted with it.

Predictive Enrollment

Site Risk Scoring

Monitoring Triage

Signal Detection (PV)

Data-Lake Generation

Bid Scoring & VOC

Build. Transfer. Exit.You own the system in 18 months.

Build

Transfer

Exit

Molecule to approval.For founders who cannot afford to get the first trial wrong.

Discovery & Preclinical

IND / CTA Submission

Phase I FIH

Phase II POC

Phase III Pivotal

BLA / NDA Submission

Phase IV / Post-Market

RWE / RWD Programs

Pick the shape that fits your stage and runway.

Pre-IND Strategic Audit

Fractional CDO / CMO

Targeted Project Delivery

Scientific & Clinical Advisory Board

Tell us where you are.We'll tell you what we'd do next.

When a trial is
off-course,
we put it back
on target.

Personnel
& Governance

Outsourced delivery,
sponsor-retained control.

The "YES" system
— engineered, not aspirational.

Build. Transfer. Exit.
You own the system in 18 months.

Your trial is off-course.
We put it back on target.